General Hospital of Northern Theater Command
Shenyang, 110840, China
NCT Number: NCT05657470
The best reperfusion strategy for medium-sized vessel occlusion (MeVO) is not well established. Given the proven treatment effect of intra-arterial thrombolysis in patients with large vessel occlusion (LVO), the investigators hypothesized that intra-arterial tenecteplase (TNK) could increase the recanalization rate of MeVO and thus improve clinical outcome. The current study aimed to explore the safety and efficacy of intra-arterial TNK in patients with MeVO.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 2 / Phase 3
Shenyang, 110840, China
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
intra-arterial tenecteplase
Time frame: immediately after finishing intra-arterial tenecteplase
successful MeVO recanalization is defined as the expanded treatment in cerebral ischemia (eTICI) score 2b67-3 in the territory of the target occluded MeVO artery
Time frame: Day 90
mRS scores range from 0 to 6, with higher scores indicating worse outcome
Time frame: Day 90
mRS scores range from 0 to 6, with higher scores indicating worse outcome
Time frame: Day 90
mRS scores range from 0 to 6, with higher scores indicating worse outcome
Time frame: 24 (-6/+24) hours
early neurological improvement is defined as a decrease of more than 4 points or reaching 0 points in NIHSS score, compared with baseline
Time frame: 24 (-6/+24) hours
NIHSS scores range 0-42, with higher scores indicating greater stroke severity
Time frame: 7 days or at hospital discharge
Time frame: 24 (-6/+24) hours
symptomatic intracranial hemorrhage is defined as an increase in the NIHSS score of ≥4 points as a result of the intracranial hemorrhage
Time frame: 24 (-6/+24) hours
Time frame: 24 (-6/+24) hours
Time frame: 7 days
Time frame: 90 days
General Hospital of Shenyang Military Region
Other
Rescue Thrombolysis for Medium Vessel Occlusion (RESCUE-TNK): a Prospective, Randomized, Open-label, Blinded End Point, and Multicenter Trial
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04992195
Alzheimer Disease, Arterial Thromboembolism
Hong Kong
View Trial DetailsNCT05559398
Brain Diseases, Cardiovascular Diseases
Bron, France
View Trial DetailsNCT04042584
Brain Diseases, Cardiovascular Diseases
Bordeaux, France
View Trial DetailsNCT06641050
Brain Diseases, Cardiovascular Diseases
Istanbul, Turkey (Türkiye)
View Trial Details